# EDGAR Filing Document

**Accession Number:** 0001889109
**File Stem:** 0001104659-23-020864
**Filing Date:** 2023-2
**Character Count:** 9514
**Document Hash:** 50b05ee1c3ee1c616f4d8722c8a7647a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-020864.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001104659-23-020864

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BELITE BIO, INC
- **CENTRAL INDEX KEY:** 0001889109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93970
- **FILM NUMBER:** 23623040

**BUSINESS ADDRESS:**
- **STREET 1:** 5820 OBERLIN DRIVE, SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-246-6240

**MAIL ADDRESS:**
- **STREET 1:** 5820 OBERLIN DRIVE, SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lin Bioscience International Ltd.
- **CENTRAL INDEX KEY:** 0001965750
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 36F., NO. 68, SEC. 5, ZHONGXIAO E. RD.,
- **STREET 2:** XINYI DISTRICT
- **CITY:** TAIPEI CITY
- **STATE:** F5
- **ZIP:** 110
- **BUSINESS PHONE:** 886287805008

**MAIL ADDRESS:**
- **STREET 1:** 36F., NO. 68, SEC. 5, ZHONGXIAO E. RD.,
- **STREET 2:** XINYI DISTRICT
- **CITY:** TAIPEI CITY
- **STATE:** F5
- **ZIP:** 110

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934\***

---

| |
|:---|
| **Belite Bio, Inc** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Name of Issuer) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Ordinary shares, par value US$0.0001 per share** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Title of Class of Securities) |
| **07782B 104\*\*** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CUSIP Number) |
| **December 31, 2022** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Date of Event which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

◻ Rule 13d-1(b)

◻ Rule 13d-1(c)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;⌧ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

\*\* There is no CUSIP number assigned to the ordinary shares of the Issuer ("Ordinary Shares"). CUSIP number 07782B 104 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on NASDAQ Capital Market under the symbol "BLTE". Each ADS represents one Ordinary Share.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**CUSIP No. 07782B 104** | &nbsp;&nbsp;**SCHEDULE 13G** | &nbsp;&nbsp;**Page 2 of** 4 **Pages** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;1 | &nbsp;&nbsp; NAMES OF REPORTING PERSONS<br>Lin Bioscience International Ltd. |
| &nbsp;&nbsp;2 | &nbsp;&nbsp; CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> (a) ◻<br> (b) ◻ |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;4 | &nbsp;&nbsp; CITIZENSHIP OR PLACE OF ORGANIZATION<br>Cayman Islands |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY <br>EACH <br>REPORTING<br>PERSON WITH | &nbsp;&nbsp;5 | &nbsp;&nbsp; SOLE VOTING POWER<br>16,428,597 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY <br>EACH <br>REPORTING<br>PERSON WITH | &nbsp;&nbsp;6 | &nbsp;&nbsp; SHARED VOTING POWER<br>0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY <br>EACH <br>REPORTING<br>PERSON WITH | &nbsp;&nbsp;7 | &nbsp;&nbsp; SOLE DISPOSITIVE POWER<br>16,428,597 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY <br>EACH <br>REPORTING<br>PERSON WITH | &nbsp;&nbsp;8 | &nbsp;&nbsp; SHARED DISPOSITIVE POWER<br>0 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;9 | &nbsp;&nbsp; AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>16,428,597 |
| &nbsp;&nbsp;10 | &nbsp;&nbsp; CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ◻ |
| &nbsp;&nbsp;11 | &nbsp;&nbsp; PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>65.98%<sup>(1)</sup> |
| &nbsp;&nbsp;12 | &nbsp;&nbsp; TYPE OF REPORTING PERSON<br>CO |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The percentage is calculated based upon an aggregate of 24,898,908 Ordinary Shares outstanding as of
December 31, 2022, which is based on the information provided by the Issuer.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**CUSIP No. 07782B 104** | &nbsp;&nbsp;**SCHEDULE 13G** | &nbsp;&nbsp;**Page 3 of** 4 **Pages** |

---

---

| | |
|:---|:---|
| **Item 1(a)** | <u>Name of Issuer</u>: |

---

Belite Bio, Inc (the "Issuer")

---

| | |
|:---|:---|
| **Item 1(b)** | <u>Address of Issuer's Principal Executive Offices</u>: |

---

5820 Oberlin Drive, Suite 101,

San Diego, CA 92121

United States of America

---

| | |
|:---|:---|
| **Item 2(a)** | <u>Name of Persons Filin</u>g: |

---

This Schedule 13G is filed on behalf of Lin Bioscience International Ltd. ("Reporting Person")

---

| | |
|:---|:---|
| **Item 2(b)** | <u>Address of Principal Business Office or, If None, Residence</u> |

---

The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan.

---

| | |
|:---|:---|
| **Item 2(c)** | <u>Citizenshi</u>p |

---

Lin Bioscience International Ltd. is a company organized under the laws of the Cayman Islands.

---

| | |
|:---|:---|
| **Item 2(d)** | <u>Title of Class of Securities</u>: |

---

Ordinary Shares, par value $0.0001 per share

---

| | |
|:---|:---|
| **Item 2(e)** | <u>CUSIP Number</u>: |

---

07782B 104

**Item 3.** <u>Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):</u>

Not applicable.

**Item 4.** <u>Ownershi</u>p

The information for the Reporting Person contained in rows 5-11 of the cover page and Item 2(a) is incorporated herein by reference.

**Item 5.** <u>Ownership of Five Percent or Less of a Class</u>

Not applicable.

**Item 6.** <u>Ownership of More Than Five Percent on Behalf of Another Person</u>

Not applicable.

**Item 7.** <u>Identification and Classification of Subsidiar</u>y <u>Which Acquired the Securi</u>ty <u>Bein</u>g <u>Reported on b</u>y <u>the Parent Holdin</u>g <u>Compan</u>y <u>or Control Person</u>

Not applicable.

**Item 8.** <u>Identification and Classification of Members of the Grou</u>p

Not applicable.

**Item 9.** <u>Notice of Dissolution of Grou</u>p

Not applicable.

**Item 10.** <u>Certifications</u>

Not applicable.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**CUSIP No. 07782B 104** | &nbsp;&nbsp;**SCHEDULE 13G** | &nbsp;&nbsp;**Page 4 of** 4 **Pages** |

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023

---

| | |
|:---|:---|
| Lin Bioscience International Ltd. | Lin Bioscience International Ltd. |
| By: | /s/ Yu-Hsin Lin |
| Name: | Yu-Hsin Lin |
| Title: | Director |

---